GHRP-6
Also known as: Growth Hormone-Releasing Peptide-6, Hexapeptide-2, SKF-110679, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
The original GH-releasing peptide — a synthetic hexapeptide that stimulates a growth hormone pulse and strongly increases appetite via the ghrelin receptor. The hormonal and hunger effects are measurable; clinical benefits are unproven. Sold as a research chemical, not an approved drug.
Not approved by the FDA for any use. Historically important as the first synthetic GH secretagogue used to probe the GH axis, but sold today for laboratory research only.
What it is
GHRP-6 is a synthetic hexapeptide — six amino acids — and the original growth-hormone-releasing peptide, described by Cyril Bowers in the 1980s. It activates the ghrelin receptor (GHS-R1a), triggering both a growth hormone (GH) pulse and, distinctively, a strong hunger signal. Every later GH secretagogue, including GHRP-2, ipamorelin, and MK-677, descends from work that started with GHRP-6.
What it’s approved or studied for
GHRP-6 is not FDA-approved for any use. Its historical importance is as a research and physiology tool for studying the GH axis and the ghrelin receptor — not as an approved treatment. The muscle, recovery, and body-composition uses it is marketed for are not established in controlled human trials.
What human evidence exists
The human evidence is about hormones and hunger, not clinical outcomes. Decades of pharmacology show GHRP-6 reliably provokes a GH pulse (Grade C — a biomarker effect), and it is the most potent appetite stimulant of the classic GHRPs (Grade C for increased food intake). Beyond that, the picture is thin: no adequate controlled trials show GHRP-6 improves muscle, recovery, or body composition (Grade E). Long-term human safety is Grade U — unknown.
The major unknowns
Whether the GH pulse GHRP-6 produces yields any durable benefit — and at what cost — is unresolved. Its pronounced appetite effect complicates any body-composition rationale. Long-term consequences of chronic GH-axis stimulation, including sustained IGF-1 elevation and effects on prolactin, cortisol, and glucose handling, are uncharacterized in humans. Research-chemical supply is unregulated, so vial identity and purity are uncertain.
Most important safety considerations
There is no controlled long-term human safety data, so long-term safety is genuinely unknown. Expect strong hunger; higher doses can raise cortisol and prolactin. It is prohibited in sport under WADA’s S2 category, product quality is uncontrolled, and it is not a legal therapeutic. This page summarizes the research record; it is not medical advice or an endorsement of use.
Evidence by outcome
Each outcome is graded on its own evidence — a compound can be strong for one use and unproven for another. See how we grade.
Reliably provokes a GH pulse in short human studies — a biomarker effect, not a clinical outcome. — As the prototype GH secretagogue, GHRP-6 has decades of human pharmacology showing dose-dependent GH release. This is a pharmacodynamic marker, not a demonstrated health benefit.
Produces strong, rapid appetite stimulation via the ghrelin receptor. — GHRP-6 is the most orexigenic of the classic GHRPs; hunger typically rises within minutes of dosing, consistent with its ghrelin-mimetic action.
Not demonstrated in controlled human trials. — There are no adequate controlled trials showing GHRP-6 improves muscle mass, fat loss, or body composition in people, despite marketing to that effect.
No controlled human evidence.
Unknown — no controlled long-term human safety data exist. — GHRP-6 can raise cortisol and prolactin at higher doses; consequences of chronic GH-axis stimulation in humans are uncharacterized.
Safety
Common adverse effects
- Marked increase in hunger
- Flushing
- Transient rises in cortisol and prolactin at higher doses
- Injection-site reactions reported anecdotally
- Water retention
Serious risks
- Unknown long-term risk profile; sustained IGF-1 elevation and effects on insulin sensitivity are theoretical concerns; unregulated product quality and contamination risk
Contraindications
- No human contraindication data; not approved for human therapeutic use
References